Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG-1000 Efficacy and Safety in Acute Uncomplicated Influenza
NCT04706468Phase 2Completed
- Sponsor
- TaiGen Biotechnology Co., Ltd.
- Start
- Dec 2020
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TG-1000 in influenza, sponsored by TaiGen Biotechnology Co., Ltd.. Started Dec 2020; status: completed.
02
Drugs
TG-1000
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04706468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04706468.